SPINRAZA is a modified antisense oligonucleotide designed to target an underlying cause of motor neuron loss in SMA3
SPINRAZA has more than 8 years of clinical trial follow-up10
If patients or caregivers are experiencing nonmedical barriers to accessing treatment–such as the cost of SPINRAZA–Biogen may be able to help
†Based on commercial patients, early access patients, and clinical trial participants through September 2023.11
‡SPINRAZA clinical studies included patients from 3 days to 16 years of age at first dose and did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger patients. Pivotal studies did not include adult patients.3
“Around age 32, I had moved across the
country and started working with a new doctor. I was
feeling weaker but learning to accept it. My doctor mentioned a treatment to me
called SPINRAZA.”